Navigation Links
Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
Date:10/23/2013

ALISO VIEJO, Calif., Oct. 23, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host a live webcast in conjunction with its Investor Relations Day on Tuesday, October 29, 2013 at 12:30 p.m. ET in New York City.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

To view and listen to the webcast please visit our website at http://ir.avanir.com. Visitors will also be able to view and listen to an archive copy of the webcast found in the Investor Relations section of www.avanir.com. The archive will be available for 30 days following the event.

For more information on the Investor Relations Day please refer to contact information within this press release.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Burns McClellan Contact
Ami Bavishi'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
2. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
4. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
5. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
6. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
7. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
8. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
9. Avanir Pharmaceuticals to Participate in Two Conferences in August
10. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.C. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Medical Equipment, Inc. for the third straight year, ... Inc. 500|5000, an exclusive ranking of the nation,s ... comprehensive look at the most important segment of ... Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and ...
(Date:8/21/2014)... 21, 2014  Seventy-one percent of Americans believe the abuse ... serious public health and safety issue in the ... released today by Repass & Partners, a Cincinnati ... understand the severity of the prescription medication abuse problem and ... very serious health situation facing our country," Rex Repass ...
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
... (Nasdaq: MYL ) today announced that Mylan ... a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor ... connection with Mylan Specialty,s Abbreviated New Drug Application (ANDA) ... 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex® 2
(Date:8/22/2014)... DC (PRWEB) August 22, 2014 Paying ... little easier in the coming year for four nurse ... the National League for Nursing Foundation for Nursing ... – will share $28,000, $10,000 more than in 2013, ... Ann Kerr Endowment and Elizabeth Isaac Marcil Endowment Funds, ...
(Date:8/22/2014)... August 22, 2014 Eagerly embracing intended ... fertility destination, and now offers the top male infertility ... infertility specialists. The fertility network of IVFinMexico.com ... to world-class reproductive care, female and male infertility, advanced ... to the standards so eminently set by company CEO ...
(Date:8/22/2014)... 2014 (HealthDay News) -- An intensive effort to sterilize feral ... shelter in Florida and euthanized, a new study reveals. ... slow their intake into animal control," Dr. Julie Levy, a ... of Veterinary Medicine, said in a university news release. ... a big impact," she explained, "so we wanted to pick ...
(Date:8/22/2014)... A national leader in home delivery of medical supplies, ... grow. , Headquarters for the provider of sterile-use catheters and ... 8516 N.W. Expressway in Oklahoma City. , Rapid growth ... places to work by OKCBiz magazine – demanded more space ... the past two years, and staff count grew 30 percent ...
(Date:8/22/2014)... Home Care Assistance of Centennial , ... is proud to announce the next installment in its ... feature Dr. Suzanne Steinbaum, attending cardiologist and Director of ... York City, National Spokesperson for the American Heart Association’s ... the issues surrounding women and heart disease, what heart ...
Breaking Medicine News(10 mins):Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Neutering Project Curbed Feral Cat Population 2Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3
... FRANCISCO, Jan. 28 Rodan + Fields Dermatologists, the,clinical skincare ... and Kathy Fields, M.D., is pleased to,announce the recent addition ... "Rodan + Fields is the most exciting ... retail, we should expect their future to,be bright," says Henry. ...
... The International Medical Interpreters Association (IMIA) unveiled ... its organization. "Our revised bylaws do not stipulate ... distributed among different states and this initiative will ... President.The organization will now have a key representative ...
... Jan. 28 Dr. Michael Forster of the ... of the University of Southern California,s ... may not be a key to living longer. ... researchers were recently published in several scientific journals ...
... 28 The Frost & Sullivan ,2009 European ... Award, is presented to VTS Medical Systems, LLC, ... needs of European hospitals with its value-added products ... ergonomically designed VividImage(R) series, the company is set ...
... 28 Cardiogenesis Corporation (Pink Sheets: CGCP), ... ischemic cardiac disease and the market leader ... sponsored an educational symposium titled "Advancements in ... attended by over 40 cardiothoracic surgeons.The Program ...
... Resubmission Within 60 Days-MISSISSAUGA, ON, Jan. 28 /PRNewswire-FirstCall/ ... drug development company focused on the research and ... the skin using its topical and transdermal drug ... completed all of the studies that will support ...
Cached Medicine News:Health News:Direct Selling Luminary, Robert M. Henry, Partners With Rodan + Fields(R) Dermatologists as Strategic Business Advisor 2Health News:International Medical Interpreter Association Appoints IMIA State Representatives 2Health News:UNT Health Science Center Researchers Discover Eating Less May Not Increase Life Expectancy 2Health News:UNT Health Science Center Researchers Discover Eating Less May Not Increase Life Expectancy 3Health News:Frost & Sullivan Bestows Product Line Strategy Leadership Award to VTS Medical Systems, LLC 2Health News:Frost & Sullivan Bestows Product Line Strategy Leadership Award to VTS Medical Systems, LLC 3Health News:Frost & Sullivan Bestows Product Line Strategy Leadership Award to VTS Medical Systems, LLC 4Health News:Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco 2Health News:Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco 3Health News:Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco 4Health News:Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies 2Health News:Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies 3Health News:Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies 4
Calibration plasmas for Assays of Low Molecular Weight Heparins (LMWH)using the Anti-Xa method on STA© Analyzers....
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: